Evaluation of Efficacy and Safety of Wishbone HA as Bone Graft Substitute, a Pre-market Clinical Investigation

August 19, 2019 updated by: Wishbone SA

Prospective, Single Center, Pivotal Investigation to Investigate Efficacy and Safety of WISHBONE HA, Used as Bone Graft Substitute for Different Indications Where Bone Grafting Procedures Are Required Before Implant Placement.

Evaluation of efficacy and safety of Wishbone HA as bone graft substitute, a pre-market clinical investigation.

Group1: Extraction Socket management Group 2: Sinus lift

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Anticipated)

47

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Subject signed the informed consent form
  • Subject is ≥18 and ≤ 80 years old.
  • Subject presented in need of:

    1. tooth extraction without estimated need of connective tissue grafting OR
    2. defect in the upper jaw requiring sinus lift with or without lateral augmentation procedure prior to implant placement
  • The subject is willing and able to comply with all investigation related procedures (such as exercising oral hygiene and attending all follow-up visits).
  • Full-mouth bleeding score (FMBS) lower than 25%
  • Full-mouth plaque score (FMPI) lower than 25%
  • The subject displays no clinical contraindications for a 2-stage surgical procedure

Exclusion Criteria:

  • Less than 2 mm of remaining keratinized mucosa
  • Severe vertical resorption of the crest (except internal resorptions, i.e. expanded sinuses)
  • Ridge with prior bone augmentation procedure performed (i.e ridge preservation)
  • Any disorders in the planned implant area such as previous tumors, chronic bone disease.
  • Alcohol or drug abuse as noted in subject records or in subject history.
  • Any ongoing application of interfering medication (steroid therapy, bisphosphonate, etc).
  • Reason to believe that the treatment might have a negative effect on the subject's overall situation (psychiatric problems), as noted in subject records or history.
  • Smoking: >10 cigarettes per day

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Measure of the bone augmentation success
Time Frame: 4 months after procedure
Group 1 - Extraction Socket Management: Efficacy endpoint based on the bone augmentation success (bone gain after bone augmentation procedure) measured by Cone Beam CT
4 months after procedure
Measure of the bone augmentation success
Time Frame: 6 months after procedure
Group 2 - Sinus lift: Efficacy endpoint based on the bone augmentation success (bone gain after bone augmentation procedure) measured by Cone Beam CT
6 months after procedure

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Safety endpoint: Collection of all device related adverse events
Time Frame: 4 months after procedure
Group 1 - Extraction Socket Management: Collection of all device related adverse events reported by the investigator and by the patient from the time of procedure up to the time of implant insertion: Abnormal tissue reaction of the surrounding area, Not expected complications, Loss of material, Additional signs of Inflammation, Wound dehiscence, Membrane exposure, Persistent feeling of discomfort at the gingival incision
4 months after procedure
Safety endpoint: Collection of all device related adverse events
Time Frame: 6 months after procedure
Group 2 - Sinus lift: Collection of all device related adverse events reported by the investigator and by the patient from the time of procedure up to the time of implant insertion: Abnormal tissue reaction of the surrounding area, Not expected complications, Loss of material, Additional signs of Inflammation, Wound dehiscence, Membrane exposure, Persistent feeling of discomfort at the gingival incision
6 months after procedure
Procedure success: ability to successfully perform the implants placement
Time Frame: 4 months after procedure
Group 1 - Extraction Socket Management: The procedure is a success if the bone is sufficient for implant placement and implant can be placed successfully with sufficient good primary stability (>10Ncm) measured using a torque wrench.
4 months after procedure
Procedure success: ability to successfully perform the implants placement
Time Frame: 6 months after procedure
Group 2 - Sinus lift: The procedure is a success if the bone is sufficient for implant placement and implant can be placed successfully with sufficient good primary stability (>10Ncm) measured using a torque wrench.
6 months after procedure
Site preparation: need for under or over preparation of the osteotomy
Time Frame: 4 months after procedure

Group 1 - Extraction Socket Management: If the second CBCT shows favourable results, implant placement will be performed. Depending on the clinician's choice, a CAD-CAM surgical guide could be prepared to facilitate proper positioning of the implant(s). Access to the bone crest will be made with an as minimally-invasive surgical approach as possible, depending on the surgeon's choice.

The drilling procedure will be performed according to the manufacturer's instructions for the placement the implant(s); during this drilling procedure, the clinician will determine if the bone quality is sufficient for placing the implant(s).

4 months after procedure
Site preparation: need for under or over preparation of the osteotomy
Time Frame: 6 months after procedure

Group 2 - Sinus lift: If the second CBCT shows favourable results, implant placement will be performed. Depending on the clinician's choice, a CAD-CAM surgical guide could be prepared to facilitate proper positioning of the implant(s). Access to the bone crest will be made with an as minimally-invasive surgical approach as possible, depending on the surgeon's choice.

The drilling procedure will be performed according to the manufacturer's instructions for the placement the implant(s); during this drilling procedure, the clinician will determine if the bone quality is sufficient for placing the implant(s).

6 months after procedure
Assessment of the bone quality and bone quantity
Time Frame: 4 months after procedure
Group 1 - Extraction Socket Management: Bone quality and bone quantity will be assessed following Lekholm and Zarb classification.
4 months after procedure
Assessment of the bone quality and bone quantity
Time Frame: 6 months after procedure
Group 2 - Sinus lift: Bone quality and bone quantity will be assessed following Lekholm and Zarb classification.
6 months after procedure
Implant survival
Time Frame: 1 year after after definitive prosthesis delivery

Implant survival will be assessed by answering if:

  1. The implant remains in the jaw
  2. The implant is damaged to the extent that it cannot be restored
1 year after after definitive prosthesis delivery
Implant success
Time Frame: 1 year after after definitive prosthesis delivery

Implant Success will be defined in accordance with the criteria proposed by van Steenberghe. Answering yes or no to the following statements:

  1. The implant causes allergic, toxic or gross infectious reactions either locally or systemically.
  2. The implant offers anchorage to a functional prosthesis.
  3. The implant shows signs of fracture or bending.
  4. The implant shows signs of peri-implant radiolucency on an intra-oral radiograph using a paralleling technique strictly perpendicular to the implant-bone interface.
  5. The implant shows mobility when individually tested by tapping or rocking with a hand instrument.
1 year after after definitive prosthesis delivery
Papilla index evaluation
Time Frame: 1 year after definitive prosthesis delivery
The soft tissue contour adjacent to the implant is assessed from definitive prosthetic placement to the 1-year follow up visit using the papilla index according to Jemt 1997
1 year after definitive prosthesis delivery
Plaque index evaluation
Time Frame: 1 year after definitive prosthesis delivery

The plaque accumulation is assessed using the modified Plaque Index (mPlI) according to Mombelli et.al:

0 = No detectible plaque

1 = Plaque only recognized by running a probe across the marginal surface of the implant 2 = Plaque can be seen by the naked eye 3 = Abundance of soft matter

1 year after definitive prosthesis delivery
Bleeding index evaluation
Time Frame: 1 year after definitive prosthesis delivery

The bleeding tendency is assessed by a modified Sulcus Bleeding Index (mBI) according to Mombelli et. al:

0 = No bleeding when a periodontal probe is passed along the gingival margin adjacent to the implant

  1. = Isolated bleeding spots visible
  2. = Blood forms a confluent red line on the margin 3 = Heavy or profuse bleeding
1 year after definitive prosthesis delivery
Keratinized mucosa evaluation
Time Frame: 1 year after definitive prosthesis delivery

Classification will be performed as:

0 = No keratinized mucosa around the implant.

1= Keratinized mucosa Measurement in mm of the keratinized mucosa in the apico-coronal direction using a periodontal probe

1 year after definitive prosthesis delivery
Patient Oral health profile evaluation
Time Frame: 1 year follow-up visit
The quality of life will be assessed at all visits by a questionnaire which is going to be completed be the subject. The shortened version from Brennan et al., OHIP-14 has been adopted for use in this investigation
1 year follow-up visit

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 8, 2019

Primary Completion (Anticipated)

February 28, 2020

Study Completion (Anticipated)

May 31, 2021

Study Registration Dates

First Submitted

August 7, 2019

First Submitted That Met QC Criteria

August 12, 2019

First Posted (Actual)

August 13, 2019

Study Record Updates

Last Update Posted (Actual)

August 21, 2019

Last Update Submitted That Met QC Criteria

August 19, 2019

Last Verified

August 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • 20181207_WHA_CIP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bone Loss in Jaw

Clinical Trials on Bone graft substitute

Subscribe